Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

BRIEF-Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

Published 18/04/2017, 03:44 pm
BRIEF-Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

April 18 (Reuters) - Geneuro SA GNRO.PA :

* Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

* Type 1 diabetes is second GNbAC1's indication after multiple sclerosis

* Placebo controlled randomized phase 2a study evaluates drug candidate targeting potential causal factor in 60 recently diagnosed adults

* Results expected by Q3 2018

* Placebo-Controlled, randomized phase 2a study will evaluate GNbAC1 in 60 recently diagnosed adults at over 10 centers in Australia

* Primary endpoint will be safety in this new patient population Source text for Eikon: ID:nBw11VJ7Xa Further company coverage: GNRO.PA

(Gdynia Newsroom:)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.